Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4216361
Max Phase: Preclinical
Molecular Formula: C33H40Cl2N6O7S
Molecular Weight: 735.69
Molecule Type: Small molecule
Associated Items:
ID: ALA4216361
Max Phase: Preclinical
Molecular Formula: C33H40Cl2N6O7S
Molecular Weight: 735.69
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=C(NC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)c1ccn(Cc2cc(Cl)c(CN3CSC[C@H]3C(=O)N3CCN(C4CC4)c4ccccc43)cc2Cl)n1
Standard InChI: InChI=1S/C33H40Cl2N6O7S/c34-22-12-20(15-39-8-7-24(37-39)32(47)36-13-28(43)30(45)31(46)29(44)16-42)23(35)11-19(22)14-38-18-49-17-27(38)33(48)41-10-9-40(21-5-6-21)25-3-1-2-4-26(25)41/h1-4,7-8,11-12,21,27-31,42-46H,5-6,9-10,13-18H2,(H,36,47)/t27-,28-,29+,30+,31+/m0/s1
Standard InChI Key: WHXVSGSTNQQYPW-OXMBMXHISA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 735.69 | Molecular Weight (Monoisotopic): 734.2056 | AlogP: 1.29 | #Rotatable Bonds: 13 |
Polar Surface Area: 174.86 | Molecular Species: NEUTRAL | HBA: 12 | HBD: 6 |
#RO5 Violations: 3 | HBA (Lipinski): 13 | HBD (Lipinski): 6 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 12.63 | CX Basic pKa: 3.60 | CX LogP: 1.18 | CX LogD: 1.18 |
Aromatic Rings: 3 | Heavy Atoms: 49 | QED Weighted: 0.15 | Np Likeness Score: -0.90 |
1. Chen T, Reich NW, Bell N, Finn PD, Rodriguez D, Kohler J, Kozuka K, He L, Spencer AG, Charmot D, Navre M, Carreras CW, Koo-McCoy S, Tabora J, Caldwell JS, Jacobs JW, Lewis JG.. (2018) Design of Gut-Restricted Thiazolidine Agonists of G Protein-Coupled Bile Acid Receptor 1 (GPBAR1, TGR5)., 61 (17): [PMID:30141927] [10.1021/acs.jmedchem.8b00308] |
Source(1):